 CONCORD, Calif.--BUSINESS WIRE--Cerus Corporation Nasdaq: CERS today announced that the US Food and Drug Administration FDA has granted approval of the INTERCEPT Blood System for Cryoprecipitation. The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. After thawing, Pathogen Reduced Cryoprecipitated Fibrinogen Complex remains transfusion-ready at roo 